subscribeSubscribe
FDA approves decade-old Pfizer drug for rare childhood leukemia

FDA approves decade-old Pfizer drug for rare childhood leukemia
Nicole DeFeudis ENDPTS
28 Sep 2023
Share Share
Amber Specialty Added to Pfizer’s Limited Distribution Network

Amber Specialty Added to Pfizer’s Limited Distribution Network
BUSINESSWIRE
03 Aug 2022
Share Share
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR

Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR
PRNEWSWIRE
08 Dec 2020
Share Share
Novartis’ phase III ASCEMBL study of asciminib vs bosutinib meets primary

Novartis’ phase III ASCEMBL study of asciminib vs bosutinib meets primary
PHARMABIZ
26 Aug 2020
Share Share
FDA Confirms Paragraph IV Patent Challenge of Bosulif 203341 (Bosutinib) Tablets

FDA Confirms Paragraph IV Patent Challenge of Bosulif 203341 (Bosutinib) Tablets
FDA
12 Dec 2018
Share Share
List of Paragraph IV Patent Certifications (PPIV) as of December 3, 2018

List of Paragraph IV Patent Certifications (PPIV) as of December 3, 2018
FDA
12 Dec 2018
Share Share
Biogen, Ionis collaborate to identify therapies to treat spinal muscular atrophy

Biogen, Ionis collaborate to identify therapies to treat spinal muscular atrophy
PHARMABIZ
20 Dec 2017
Share Share
Avillion Announces US Approval of Pfizer`s BOSULIF® (bosutinib)

Avillion Announces US Approval of Pfizer`s BOSULIF® (bosutinib)
PR NEWSWIRE
19 Dec 2017
Share Share
Pfizer, Avillion file for Bosulif expansion

Pfizer, Avillion file for Bosulif expansion
Selina McKee PHARMA TIMES
31 Aug 2017
Share Share
U.S. FDA & EMA Accept Regulatory Submissions for BOSULIF® (bosutinib)

U.S. FDA & EMA Accept Regulatory Submissions for BOSULIF® (bosutinib)
BUSINESSWIRE
29 Aug 2017
Share Share